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The paraoxonase 1 (PON1) enzyme detoxifies 
organophosphate (OP) pesticides, which are 
known neurotoxicants at high doses (Costa 
et al. 2005). PON1 also inhibits low-density 
lipoprotein oxidation, a marker of oxidative 
stress (Li et al. 2003). Several common poly-
morphisms in the coding (e.g., PON1192) 
and promoter (e.g., PON1–108) regions of 
the PON1 gene influence both the quantity 
and catalytic efficiency of the PON1 enzyme 
(Brophy et al. 2001; Li et al. 2000), meas-
ured against specific substrates, such as ary-
lesterase (ARYase) and paraoxonase (POase) 
activity.
PON1 polymorphisms and/or enzyme 
measurements have been associated with vari-
ous diseases of the nervous system, including 
Alzheimer’s disease (Erlich et al. 2006; Leduc 
and Poirier 2008; Paragh et al. 2002), brain 
tumors (Kafadar et al. 2006), vascular demen-
tia (Paragh et al. 2002), amyotrophic lateral 
sclerosis (Saeed et al. 2006; Slowik et al. 
2006), ischemic stroke (Voetsch et al. 2002, 
2004), and Parkinson disease (Zintzaras and 
Hadjigeorgiou 2004). Gulf War syndrome, 
which some have hypothesized may be attrib-
utable to exposure to an OP agent (Golomb 
2008), has also been associated with low 
PON1 ARYase (Haley et al. 1999) and POase 
(Mackness et al. 2000) measurements. PON1 
polymorphisms or enzyme activity may also 
play a role in psychiatric disease such as 
schizophrenia (Kucukali et al. 2008), depres-
sion (Lawlor et al. 2007), and anxiety (Sklan 
et al. 2004). In addition, PON1192 genotype 
and PON1 enzyme measurements have been 
associated with childhood autism (Pasca et al. 
2006, 2010), at least in certain populations 
(D’Amelio et al. 2005).
An individual’s susceptibility to the effects 
of specific OP pesticide exposure may be 
determined by their PON1 genotypes and 
expression (Li et al. 2000). PON1 enzyme 
measurements vary widely in humans (Cole 
et al. 2003; Costa et al. 2005; Holland 
et al. 2006), and measurements in fetuses 
and children up to at least 7 years of age 
are much lower than those in adults (Chen 
et al. 2003; Furlong et al. 2006; Huen et al. 
2010), thus presenting a potential period of 
greater vulnerability to OP pesticide toxic-
ity and oxidative stress. Transgenic newborn 
mice expressing PON1192Q showed greater 
inhibition of brain acetylcholinesterase after 
chlorpyrifos oxon exposure than did those 
with PON1192R (Cole et al. 2003). In a birth 
cohort study from New York, an associa-
tion between abnormal neonatal reflexes and 
maternal dimethyl OP pesticide exposure (as 
measured by urinary metabolites) was found 
only in children with lower levels of POase 
expression, although an association between 
abnormal reflexes and urinary diethyl phos-
phate (DE) metabolites was observed regard-
less of POase expression (Engel et al. 2007).
In our longitudinal birth cohort, the 
Center for Health Assessment of Mothers 
and Children of Salinas (CHAMACOS) 
study, we previously reported high exposure 
to OP pesticides, as measured by urinary 
dialkyl phosphate (DAP) metabolite levels, 
among pregnant women living in the agri-
cultural Salinas Valley of California, rela-
tive to levels in women of reproductive age 
(18–40 years) participating in the National 
Health and Nutrition Examination Survey 
(NHANES) (Bradman et al. 2005). We also 
observed associations between maternal DAP 
levels during pregnancy, particularly dimethyl 
phosphates (DMs; resulting from exposure to 
DM pesticides), and CHAMACOS 2-year-
olds’ mental development as assessed on the 
Bayley Scales of Infant Development (Bayley 
1993). Maternal report of symptoms of per-
vasive development disorder (PDD) in the 
clinical range on the Child Behavior Checklist 
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Ba c k g r o u n d: Paraoxonase 1 (PON1) detoxifies oxon derivatives of some organophosphate (OP) 
pesticides, and its genetic polymorphisms influence enzyme activity and quantity. We previously 
reported that maternal urinary concentrations of dialkyl phosphate (DAP) metabolites, a marker of 
OP pesticide exposure, were related to poorer mental development and maternally reported symp-
toms consistent with pervasive developmental disorder (PDD) in 2-year-olds participating in the 
Center for the Health Assessment of Mothers and Children of Salinas (CHAMACOS) study.
oB j e c t i v e: We determined whether PON1 genotypes and enzyme measurements were associated 
with child neurobehavioral development and whether PON1 modified the association of in utero 
exposure to OPs (as assessed by maternal DAPs) and neurobehavior.
Me t h o d s: We measured DAP concentrations in maternal urine during pregnancy, PON1192 
and PON1–108 genotypes in mothers and children, and arylesterase (ARYase) and paraoxonase 
(POase) in maternal, cord, and 2-year-olds’ blood. We assessed 353 2-year-olds on the Mental 
Development Index (MDI) and Psychomotor Development Index (PDI) of the Bayley Scales of 
Infant Development and queried their mothers on the Child Behavior Checklist to obtain a score 
for PDD.
re s u l t s: Children with the PON1–108T allele had poorer MDI scores and somewhat poorer PDI 
scores. Children were less likely to display PDD when they or their mothers had higher ARYase 
activity and when their mothers had higher POase activity. The association between DAPs and 
MDI scores was strongest in children with PON1–108T allele, but this and other interactions 
between DAPs and PON1 polymorphisms or enzymes were not significant.
co n c l u s i o n: PON1 was associated with child neurobehavioral development, but additional 
research is needed to confirm whether it modifies the relation with in utero OP exposure.
key w o r d s : biomarkers, Child Behavior Checklist, children, DAPs, farmworker, genetic suscepti-
bility, in utero exposure, mental development, Mexican Americans, neurodevelopment, organophos-
phates, paraoxonase, pervasive developmental disorder, pesticides, PON1. Environ Health Perspect 
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(CBCL) were also associated with maternal 
DAP levels (Eskenazi et al. 2007).
In the present study, we estimated asso-
ciations between neurodevelopmental out-
comes and PON1 genotypes and with PON1 
enzyme activity measured in children at birth 
and at 2 years of age and in mothers at deliv-
ery. We also examined whether PON1 modi-
fied the associations we previously observed 
between the mothers’ DAP concentrations 
during pregnancy and their children’s neu-
robehavioral development at 2 years of age 
(Eskenazi et al. 2007).
Materials and Methods
Study subjects. The CHAMACOS study is a 
longitudinal birth cohort study of the effects 
of exposures to pesticides and other envi-
ronmental chemicals on neurodevelopment, 
growth, and respiratory disease in children 
from primarily Latino farmworker families in 
the Salinas Valley, California (Eskenazi et al. 
2003). Located in Monterey County, the 
Salinas Valley is an intensive agricultural 
area where > 235,000 kg of OP pesticides 
are applied annually (California Department 
of Pesticide Regulation 2005). A total of 
601 pregnant women were enrolled in the 
CHAMACOS study, and 528 delivered new-
borns. Mothers in the CHAMACOS cohort 
were primarily low-income, Mexican-born, 
Spanish-speaking women who were farm-
workers themselves or lived with farmworkers. 
In this analysis, we include those mothers who 
had measured levels of urinary DAP metabo-
lites during pregnancy and whose children 
were followed up to 2 years of age (n = 371). 
Most women (n = 351) and children (n = 369) 
provided a blood specimen that was genotyped 
for PON1192 and PON1–108, and a smaller 
portion of these mothers and children had 
adequate blood samples for PON1 enzyme 
measurements (n = 304, 266, and 250 for 
mothers, umbilical cord, and 2-year-olds, 
respectively) (Huen et al. 2009a, 2010). Study 
protocols were approved by the University 
of California, Berkeley, Committee for the 
Protection of Human Subjects. Written 
informed consent was obtained from all moth-
ers for themselves and their children.
Maternal interviews and neuro  behavioral 
assessments. Information on different covariates 
was collected from maternal interviews and 
medical record review. Women were inter-
viewed twice during pregnancy (mean = 13.4 
and 25.8 weeks’ gestation), shortly after 
delivery, and when children were 6 months 
and 1 and 2 years of age. Interviews were 
conducted in Spanish or English by bilin-
gual, bicultural interviewers. Mothers were 
administered the Peabody Picture Vocabulary 
Test (PPVT) (Dunn and Dunn 1981) at the 
6-month visit to assess their scholastic/cogni-
tive abilities, and the Center for Epidemiologic 
Studies Depression Scale (CES-D) (Radloff 
1977) at the 1-year visit. The Infant-Toddler 
Home Observation for Measurement of the 
Environment (HOME) instrument (Caldwell 
and Bradley 1984), a measure of the home 
and social environment, was completed when 
the children were 6 months and 1 year of age, 
and 32 of 45 items were completed at 2 years. 
Prenatal and delivery medical records were 
abstracted by a registered nurse.
Children were assessed at 2 years of age 
on the Bayley Scales of Infant Development, 
2nd edition (Bayley 1993), a test of devel-
opmental functioning of infants and young 
children comprising two subscales: the 
Mental Development Index (MDI), which 
characterizes a variety of cognitive abilities, 
and the Psychomotor Development Index 
(PDI), which characterizes large-muscle and 
fine-motor coordination. Both scales were 
administered in Spanish and/or English 
by psychometricians blind to exposure. 
Psychometricians were trained using stan-
dardized protocols and were supervised for 
quality assurance by a clinical neuropsycholo-
gist. Assessments were performed in a private 
room at the CHAMACOS research office 
or in a recreational vehicle (RV) modified to 
be a mobile testing facility. Children were 
assessed on average (mean ± SD) at 24.6 ± 1.1 
months. Each scale is standardized by age to 
mean ± SD = 100 ± 15.
At the time of the child’s 2-year assess-
ment, the mother was administered the CBCL 
for ages 1.5 to 5 years, a 99-item tool to assess 
children’s emotional/behavioral problems 
and competencies (Achenbach and Rescorla 
2000). The CBCL has been widely used in 
cross-cultural research and collects data on a 
range of behavior problems, yielding scores 
for several syndrome scales and five scales 
designed to be consistent with Diagnostic and 
Statistical Manual of Mental Disorders, 4th ed. 
(DSM-IV) diagnoses (American Psychiatric 
Association 2000). For this study, we focus 
on the results of the DSM-IV–oriented per-
vasive developmental disorder (PDD) scale, 
which includes such items as “avoids eye con-
tact,” “rocks head, body,” and “unresponsive 
to affection,” which are considered consistent 
with Asperger’s disorder and autistic disor-
der (Achenbach and Rescorla 2000). A score 
considered of “clinical” significance is > 97th 
percentile of the national normative sample.
OP pesticide exposure: DAP metabolites. 
Urine specimens were collected from the 
mother twice during pregnancy. Urine was 
aliquoted and stored at –80°C until shipment 
on dry ice to the Centers for Disease Control 
and Prevention (Atlanta, GA), where speci-
mens were analyzed using gas chromatogra-
phy/tandem mass spectrometry and quantified 
using isotope dilution calibration (Bravo et al. 
2002) for six DAP metabolites: three DMs 
(dimethylphosphate, dimethylthiophosphate, 
dimethyldithiophosphate) and three DEs 
(diethylphosphate, diethylthiophosphate, 
and diethyldithiophosphate) (Bradman et al. 
2005). These six metabolites represent the 
by-products of approximately 80% of OP 
pesticides used in the Salinas Valley. The most 
commonly used DM pesticides in the Salinas 
Valley are malathion and oxydemeton-methyl, 
and the most commonly used DE pesticides 
are diazinon and chlorpyrifos. Values below 
the limit of detection (LOD) were assigned a 
value of LOD/√ 2.
PON1 genotype and enzyme measure-
ments. Maternal blood and fetal umbilical 
cord blood were collected at the time of deliv-
ery, and child blood samples were collected at 
2 years of age using BD Vacutainers (Becton, 
Dickinson and Company, Franklin Lakes, NJ) 
as previously described (Holland et al. 2006). 
Heparinized plasma was used to assess PON1 
substrate-specific activities at each time point, 
and maternal and child genotyping was con-
ducted using DNA isolated from blood clots.
The coding polymorphism PON1192 
was genotyped using the Taqman real-time 
polymerase chain reaction (PCR) method as 
previously described (Holland et al. 2006) 
using probes custom-designed by Applied 
Biosystems, Inc. (Foster City, CA). The pro-
moter single-nucleotide polymorphism (SNP) 
PON1–108 assay required a two-part nested 
PCR strategy, where the region surround-
ing the SNP was preamplified using nonal-
lelic flanking primers. The forward primer 
sequence was 5´-ATAGACAAAGGGATC 
GATGGGCG-3´, and the reverse primer 
sequence was 5´-TTTGGCTGAAAGT 
GCTGAGCTCCTG-3´. The amplicon was 
then diluted and used as the template for 
the Amplifluor assay (Flowgen Biosciences 
Ltd., Nottingham, UK). Quality assurance 
procedures for genotyping PON1 SNPs 
included assessment of randomly distributed 
blank samples and duplicates with indepen-
dently isolated DNA from the same subjects. 
Repeated analysis (4% of samples) in several 
runs showed a high degree (> 99%) of con-
cordance. All discrepancies were resolved with 
additional genotyping.
PON1 enzyme activities toward paraoxon 
(POase) and phenyl acetate (ARYase) were 
determined using spectrophotometric meth-
ods as described by Huen et al. (2009b). The 
ARYase assay is a quantitative measure of 
PON1 enzyme level (Connelly et al. 2008; 
Kujiraoka et al. 2000), which is mostly 
affected by the promoter polymorphism 
PON1–108. In contrast, the POase substrate-
specific assay reflects both quantity and cata-
lytic efficiency of the PON1 enzyme and is 
affected primarily by the coding polymor-
phism PON1192. We refer to enzyme quan-
tity, reflected by ARYase, as PON1 enzyme PON1, organophosphates, and neurodevelopment
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levels and to POase as PON1 enzyme activity. 
When we refer to both, we use PON1 mea-
surements. All assays were performed in tripli-
cate. Quality assurance included assessment of 
repeat samples and internal controls. The aver-
age coefficient of variation (CV) for repeated 
samples ranged from 6–9%, and interassay 
variability, as measured by the average CV 
for internal control samples, was between 7% 
and 9% [for more details on validation of 
these assays for longitudinal studies, see Huen 
et al. (2009b)].
Statistical analysis. PON1 genotypes 
were examined categorically with two indi-
cator variables per model: For PON1–108, 
the CC genotype was the reference, and for 
PON1192, the RR genotype was the reference. 
Supplemental analyses were performed clas-
sifying genotypes as ordinal variables (none, 
one, or two T alleles of PON1–108 or Q alleles 
of PON1192). ARYase and POase activity in 
cord, maternal pregnancy, and blood from 
2-year-olds was examined categorically in ter-
tiles and continuously, with values normalized 
by dividing each value by the SD of the range 
of values.
DAP metabolite concentrations (nanomoles 
per liter) were summed and transformed to the 
log10 scale. We created “pregnancy” values for 
DE, DM, and total DAP concentrations by 
averaging the two log-transformed pregnancy 
measures. The two total DAP measurements 
during pregnancy were correlated (r = 0.15, 
p = 0.007) and did not differ significantly 
(paired t-test = –0.38, p = 0.71). For 22 women, 
only a single DAP measurement was available.
Statistical methods and base models were 
similar to those described previously (Eskenazi 
et al. 2007). To examine the relationship 
between PON1 and neurobehavioral develop-
ment at 2 years of age, we constructed separate 
multiple regression models for PON1 geno-
type (PON1–108 and PON1192) and enzyme 
measurements (ARYase and POase) and each 
outcome, adjusting for DAP metabolite con-
centrations and the covariates included in 
our previous analysis (Eskenazi et al. 2007). 
Specifically, all models were adjusted for 
log10-transformed total DAP, DE, or DM 
concentrations and exact age at assessment, 
sex, parity, breast-feeding duration (months), 
HOME score (continuous), maternal PPVT 
(continuous), and household income in rela-
tion to the federal poverty threshold (U.S. 
Census Bureau 2000). Models with enzyme 
measurements were also adjusted for tempera-
ture during the assay. Multiple linear regression 
models for Bayley MDI and PDI scores also 
included psychometrician (n = 4) and testing 
location (office or RV), whereas multiple logis-
tic regression models for clinical-range PDD 
also included maternal depression (assessed at 
12 months postpartum). Covariates in final 
models were categorized as noted in Table 1 
unless otherwise specified above. To preserve 
the size of the analytic population, each miss-
ing covariate value was imputed by randomly 
selecting a value from participants with non-
missing values. In models of genotype, tests for 
trend were performed by substituting 0, 1, or 
2 to represent the number of PON1–108 T or 
PON1192 Q alleles. Studies suggest that PON1 
status, which takes into account both enzyme 
level and PON1192 genotype, is useful for 
investigating the relationship between PON1 
and health outcomes in epidemiologic studies 
(Li et al. 2003; Richter et al. 2010). Therefore, 
to incorporate a measure of PON1 status, we 
included variables for both ARYase (as a meas-
ure of PON1 enzyme levels) and PON1192 
genotype (as a proxy measure of PON1 enzyme 
activity) within the same statistical models and 
also considered their interaction.
Potential interactions between maternal 
urinary DAP concentrations (log-transformed 
continuous variables) and PON1 genotypes 
were explored by adding interaction terms. We 
also examined interaction by number of variant 
alleles (0, 1, 2). Models for DAP concentra-
tions and neurobehavioral outcomes stratified 
by PON1 genotype are presented. Similarly, 
interactions between DAP concentrations and 
PON1 enzyme levels and activity were exam-
ined using interaction terms for DAP con-
centrations and continuous PON1 enzyme 
measurements; models stratified by tertile of 
enzyme quantity or activity are presented.
Statistical significance for main effects 
terms was based on a p-value of 0.05 and 
for interaction terms, on a p-value of 0.15. 
All analyses were performed in STATA 10.0 
(StataCorp LP, College Station, TX).
Results
Most study mothers were young (mean ± 
SD = 26.2 ± 5.2 years of age at delivery), born 
in Mexico, and married or living as married 
(Table 1). Nearly 60% were living at or below 
the federal poverty threshold. About 44% 
of the women worked in agriculture during 
pregnancy, 82% had at least one household 
member working in agriculture, and 23% 
lived near a field during pregnancy. Nearly 
all women breast-fed; median duration was 
6 months. The women’s PPVT scores were 
below the expected standardized average of 
100 (mean ± SD = 86 ± 21).
The geometric mean (GM) of the aver-
age total DAP levels for the women during 
pregnancy was 110 nmol/L [95% confidence 
interval (CI), 101–120] with a larger pro-
portion composed of DM DAP metabolites 
(GM = 77; 95% CI, 70–85) than of DE DAP 
metabolites (GM = 18; 95% CI, 16–19). The 
children’s mean ± SD scores were 85 ± 12 on 
the Bayley MDI and 98 ± 11 on the Bayley 
PDI. Based on maternal report on the CBCL, 
51 (14%) exceeded the clinical cutoff criteria 
for PDD (χ2 test, p < 0.001 comparing 14% 
observed with 3% expected).
As we previously reported, about half of 
the children were heterozygous for PON1192 
and PON1–108 (Huen et al. 2009a, 2009b), 
with allelic frequencies for both of approxi-
mately 0.5 [see Supplemental Material, Table 1 
(doi:10.1289/ehp.1002234)]. PON1–108TT 
and PON1192QQ genotype were associated 
with mostly lower enzyme measures, sug-
gesting that individuals with these genotypes 
might be more susceptible to effects of OPs. 
Table 1.  Demographic  characteristics  of 
CHAMACOS mothers with children followed to 
2 years of age: Salinas Valley, California, 2000–2001 
(n = 371).
Characteristic n (%)
Child sex
Female 189 (50.9)
Male 182 (49.1)
Maternal age at delivery (years)
18–24 153 (41.2)
25–29 123 (33.2)
30–34 63 (17.0)
≥ 35 32 (8.6)
Marital status during pregnancy
Married/living as married 307 (82.8)
Single 64 (17.3)
Parity
0 117 (31.5)
≥ 1 254 (68.5)
Maternal education during pregnancy
< 6th grade 163 (43.9)
7th–12th grade 135 (36.4)
Completed high school 73 (19.7)
Maternal country of birth
Mexico 323 (87.1)
USA 44 (11.9)
Other 4 (1.1)
Alcohol use during pregnancy
Yes 4 (1.1)
No 354 (98.9)
Smoking during pregnancy
Smoker 17 (4.6)
Nonsmoker living with smoker 28 (7.6)
Nonsmoker 326 (87.9)
Maternal depressive symptoms (CES-D ≥ 16) at 1 year
Yes 181 (50.8)
No 175 (49.2)
Breast-feeding at 2 years
Yes 30 (8.1)
No 341 (91.9)
Household incomea
≤ Federal poverty threshold 218 (58.8)
> Federal poverty threshold 153 (41.2)
Worked in agriculture during pregnancy
Yes 163 (44.2)
No 206 (55.8)
Lived with agricultural worker(s) during pregnancy
Yes 302 (82.1)
No 66 (17.9)
Lived within 200 feet of agricultural field
Yes 85 (23.0)
No 284 (77.0)
Percentages represent those of known values. Values 
are limited to participants who had a Bayley assess-
ment or maternal CBCL report performed at 24 months. 
aPoverty level compares federal poverty thresholds with 
household income divided by the number of people sup-
ported (U.S. Census Bureau 2000).Eskenazi et al.
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Neonates with PON1–108TT genotype (20.3%) 
had the lowest measures of ARYase and POase 
among PON1–108 genotypes. Neonates with 
PON1192QQ (22.9%) showed lower mea-
sures of POase than did neonates with other 
PON1192 genotypes but no significant differ-
ence in ARYase levels (Holland et al. 2006; 
Huen et al. 2009a). At 2 years of age, aver-
age POase activities and ARYase levels were 
two to three times higher than in cord blood. 
Two-year-olds showed similar POase enzyme 
patterns in relation to their genotype as when 
they were neonates. ARYase levels were some-
what higher in 2-year-olds with PON1192QQ 
than in those with other PON1192 genotypes. 
We observed similar associations between 
mother’s PON1 genotype and enzyme mea-
surements [Supplemental Material, Table 2 
(doi:10.1289/ehp.1002234)].
Children with the PON1–108T allele had 
lower average MDI and PDI scores and were 
more likely to be reported by their mothers 
as having symptoms characteristic of PDD 
(Figure 1). We saw no clear pattern of asso-
ciations with outcomes with PON1192 geno-
type. The PON1–108T allele remained associated 
with poorer performance on the Bayley MDI 
and PDI (Table 2) after adjustment for cova-
riates. Specifically, compared with children 
with PON1–108CC genotype, children with 
PON1–108CT and PON1–108TT genotypes per-
formed, respectively, 3.9 points (p = 0.004) and 
5.7 points (p = 0.001) lower on the Bayley MDI 
(p-value for trend = 0.01) and 1.4 (p = 0.27) 
and 2.8 points (p = 0.07) lower on the Bayley 
PDI (p-value for trend = 0.07). We noted 
similar patterns, albeit muted, for maternal 
genotype for PON1–108 and MDI scores [see 
Supplemental Material, Table 3 (doi:10.1289/
ehp.1002234)]. Children with the PON1–108T 
allele were slightly but not significantly more 
likely to be reported by their mothers as having 
symptoms consistent with PDD, after control-
ling for potential confounders. We found no 
clear relationship between the child’s or moth-
er’s PON1192 genotype and Bayley scores or 
maternal report of PDD symptoms, except for 
somewhat better PDI scores among children 
with PON1192QQ (p-value for trend = 0.10).
Continuous measures of ARYase and 
POase in maternal, cord, or child blood were 
not related to neurobehavioral performance 
at 2 years of age on the Bayley MDI or PDI 
(Table 3). Cord PON1 measures also were 
not associated with maternal report of PDD, 
although 2-year-old ARYase levels [odds ratio 
(OR) = 0.6; 95% CI, 0.4–0.9] and maternal 
POase activity (OR = 0.6; 95% CI, 0.4–1.0) 
were associated with decreased odds of PDD 
at 2 years of age. Results were similar when we 
categorized ARYase and POase into tertiles, 
although those in the highest tertiles of ARYase 
had the highest MDI scores (ptrend = 0.04; data 
not shown). Associations between the out-
comes and ARYase were comparable when 
we included PON1192 genotype in the model, 
and we found no evidence of statistical interac-
tion (although children with PON1192QQ and 
in the highest tertile of ARYase did have the 
highest adjusted MDI and PDI scores).
Table 4 shows the relation of maternal 
DAP levels and neurobehavioral outcomes 
stratified by child genotype. As we previously 
reported (Eskenazi et al. 2007), maternal DAP 
concentrations were negatively associated with 
child MDI scores at 2 years of age, and this 
relationship was primarily with DM DAPs. 
The interaction between genotype and DAP 
concentrations was not statistically significant 
(interaction p = 0.98); however, the inverse 
association between DAP concentrations and 
MDI scores was progressively stronger among 
children with PON1–108CT and PON1–108TT 
genotypes relative to PON1–108CC. This rela-
tionship was most apparent for DM DAP 
concentrations: For each 10-fold increase in 
maternal DM DAP levels, we observed a drop 
in child MDI scores of –2.2 points (p = 0.45) 
for children with PON1–108CC, –3.4 points 
(p = 0.09) for children with PON1–108CT, 
and –5.9 points (p = 0.03) for children with 
PON1–108TT (interaction p = 0.91). We 
observed a similar trend (albeit nonsignifi-
cant) for DE DAP concentrations and MDI 
scores by genotype. The relation between 
DAP concentrations and MDI scores did not 
differ progressively by PON1192 genotype.
We previously found no relation between 
maternal DAP concentrations and child PDI 
scores at 2 years of age, and we also observed 
no clear relation when we stratified by child 
PON1–108 (Table 4). However, we found an 
inverse association between DAP concentra-
tions and PDI scores among 2-year-olds with 
PON1192QQ (p = 0.10) and an interaction of 
DE DAP concentrations and PDI scores by 
PON1192 genotype (interaction p = 0.14).
Although we observed a strong relation 
of maternal DAP concentrations and mater-
nal report of PDD overall, we found no clear 
Figure 1. Unadjusted relationship (mean ± SD) of child PON1–108 (A) and PON1192 (B) genotypes and MDI 
and PDI scores and maternal report of PDD on the CBCL. 
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Table 2. Adjusteda association of child PON1–108 and PON1192 genotypes and neurobehavioral develop-
ment at 2 years of age: CHAMACOS study, Salinas Valley, California, 2000–2003.
Genotype nb
Bayley MDI  
β (95% CI)
p-Value 
trend
Bayley PDI 
β (95% CI)
p-Value 
trend
CBCL PDD 
OR (95% CI)
p-Value 
trend
PON1–108
CC 111 Reference < 0.01 Reference 0.07 Reference 0.14
CT 179 –3.9 (–6.6 to –1.2)# –1.4 (–3.8 to 1.0) 1.5 (0.7 to 3.3)
TT 74 –5.7 (–9.0 to –2.5)# –2.8 (–5.7 to 0.2)* 2.0 (0.8 to 5.1)
PON1192
RR 94 Reference 0.65 Reference 0.10 Reference 0.94
QR 188 –0.5 (–3.4 to 2.4) 0.3 (–2.2 to 2.9) 1.0 (0.4 to 2.2)
QQ 86 0.7 (–2.6 to 4.0) 2.4 (–0.5 to 5.4) 1.0 (0.4 to 2.4)
aAdjusted for prenatal DAPs and age at assessment, sex, parity, breast-feeding duration, HOME score, maternal PPVT, 
and household poverty status. Bayley MDI and PDI models also included psychometrician and testing location; PDD 
models also included maternal depression. bNumbers may vary slightly depending on the model. *p < 0.10. #p < 0.01.PON1, organophosphates, and neurodevelopment
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difference in the odds across strata of PON1–108 
and only a suggestion of a higher odds in chil-
dren with PON1192QQ or PON1192RR (for 
DMs). However, numbers within each stratum 
are too small to provide reliable ORs, and none 
of the interactions between DAP concentra-
tions and genotype was statistically significant. 
We observed similar, albeit weaker, associations 
between DAP concentrations and neurobehav-
ioral outcomes when we stratified results by 
maternal genotype rather than child genotype 
[Supplemental Material, Table 4 (doi:10.1289/
ehp.1002234)].
We did not observe statistically signifi-
cant interaction between DAPs and enzyme 
measurements (as a continuous measure) in 
relation to any of the neurobehavioral end 
points. We present the relation of maternal 
DAP concentrations and neurobehavioral 
outcomes within tertiles of cord and maternal 
ARYase and POase in Supplemental Material, 
Tables 5 and 6 (doi:10.1289/ehp.1002234). 
(We do not present the results stratified by 
2-year-old PON1 measurements because 
the biological mechanism of in utero expo-
sure being modified by child’s enzyme levels 
2 years later would be uncertain.) Consistent 
with results by child PON1 genotype, the 
relation of DAP concentrations and child 
MDI scores was strongest within the group 
of children with the lowest tertiles of cord 
ARYase and POase, although the pattern 
was not as clear. We observed slightly stron-
ger relationships of PDI scores and mater-
nal DAP concentrations, particularly for DE 
DAPs, among children with cord blood in 
the lowest tertile of ARYase relative to chil-
dren with higher cord blood PON1 activity. 
Maternal DAP concentrations were consis-
tently positively associated, although not sig-
nificantly, with reports of PDD across all 
tertiles of cord ARYase activity. However, 
the relationship of DAP concentrations and 
PDD was significant only in the group with 
the lowest tertile of POase. Again, relatively 
small numbers in each tertile made these esti-
mates unreliable. Results for DAP concentra-
tions and MDI scores, PDI scores, and PDD 
assessment across maternal enzyme levels and 
activities [Supplemental Material, Table 5 
(doi:10.1289/ehp.1002234)] were similar to 
those for cord blood enzyme levels.
Discussion
Our previous study demonstrated that wom-
en’s levels of OP pesticide DAP metabolites 
in urine during pregnancy are related to their 
2-year-olds’ mental development and reported 
symptoms of PDD (Eskenazi et al. 2007). In 
the present study, we examined whether these 
associations were modified by the mother 
and child’s PON1 genotypes and associated 
enzyme levels and activities. In analyses of 
PON1 and neurobehavior, we found that 
the PON1–108T allele in children was asso-
ciated with poorer Bayley MDI scores and 
with somewhat poorer Bayley PDI scores. 
Maternal, cord, and child PON1 enzyme lev-
els and activities, although related to geno-
type, were not significantly associated with 
these neurobehavioral outcomes except that 
children were less likely to display symptoms 
of PDD when they or their mothers had 
higher ARYase levels or POase activities.
Although we have observed a relationship 
of DAP concentrations and neuro  behavioral 
outcomes and of PON1 and these same 
end points, we are less certain as to whether 
genotype or enzyme measurements modify 
the association of DAP concentrations and 
neurobehavior—that is, whether a subgroup 
of children by virtue of their genetic makeup 
are more susceptible to the adverse effects of 
maternal exposure to OP pesticides during 
pregnancy. There is a suggestion with MDI 
scores that children with PON1–108T allele 
show a stronger association with OP pesticide 
exposure in utero (as measured by maternal 
DAPs), but the interaction is not significant.
PON1 has been implicated in the etiol-
ogy of a number of adult-onset neurologic 
diseases such as Parkinson and Alzheimer 
Table 3. Adjusteda association of PON1 enzyme measurements (per SD increase) in cord and child 
blood and neurobehavioral development at 2 years of age: CHAMACOS study, Salinas Valley, California, 
2000–2003.
Enzyme Mean ± SD
Bayley MDI  
[β (95% CI)]
Bayley PDI  
[β (95% CI)]
CBCL PDD  
[OR (95% CI)]
Fetal enzymes (n = 265)
ARYase 34.0 ± 16.8 0.8 (–0.6 to 2.1) –0.6 (–1.8 to 0.7) 0.8 (0.6 to 1.2)
POase 254.3 ± 165.0 0.1 (–1.3 to 1.5) –1.0 (–2.2 to 0.2) 1.0 (0.7 to 1.4)
2-year-old enzymes (n = 249)
ARYase 87.0 ± 25.1 0.4 (–1.0 to 1.8) 0.1 (–1.2 to 1.3) 0.6 (0.4 to 0.9)**
POase 665.2 ± 385.8 –0.2 (–1.6 to 1.3) –0.5 (–1.7 to 0.8) 0.8 (0.6 to 1.3)
Maternal enzymes during pregnancy (n = 302)
ARYase 133.3 ± 40.9 0.7 (–0.7 to 2.1) 0.4 (–0.8 to 1.7) 0.7 (0.5 to 1.0)*
POase 958.6 ± 599.3 –0.1 (–1.4 to 1.2) 0.0 (–1.2 to 1.2) 0.6 (0.4 to 1.0)**
aAdjusted for prenatal DAPs and age at assessment, sex, parity, breast-feeding duration, HOME score, maternal PPVT, 
household poverty status, and assay temperature. Bayley MDI and PDI models also included psychometrician and test-
ing location; PDD models also included maternal depression. *p < 0.10. **p < 0.05.
Table 4. Adjusteda associations of prenatal DAPs and neurobehavioral development at 2 years of age, 
stratified by child PON1–108 and PON1192 genotype: CHAMACOS study, Salinas Valley, California, 2000–2003.
DAP
Bayley MDI  
β (95% CI)
p-Value 
interactionb
Bayley PDI  
β (95% CI)
p-Value 
interactionb
CBCL PDD  
OR (95% CI)
p-Value 
interactionb
Total DAPs
PON1–108
CC –3.2 (–9.8 to 3.5) 0.98 –2.3 (–7.8 to 3.3) 0.89 4.2 (0.5–36.8) 0.91
CT –3.7 (–8.0 to 0.6)* –0.8 (–4.8 to 3.3) 2.0 (0.6–6.0)
TT –5.5 (–11.1 to 0.1)* –1.0 (–7.1 to 5.1) 1.9 (0.3–10.4)
PON1192
RR –6.5 (–15.6 to 2.6) 0.33 –1.7 (–8.7 to 5.4) 0.53 5.4 (0.7–44.0) 0.29
QR –1.2 (–5.2 to 2.9) 0.1 (–3.5 to 3.8) 1.2 (0.4–3.6)
QQ –6.9 (–12.8 to –0.9)** –5.1 (–11.1 to 1.0)* 5.2 (0.8–35.1)*
DM DAPs
PON1–108
CC –2.2 (–8.0 to 3.6) 0.91 –1.6 (–6.4 to 3.3) 0.87 3.3 (0.5–21.3) 0.94
CT –3.4 (–7.4 to 0.6)* –0.3 (–4.0 to 3.4) 2.2 (0.8–5.9)
TT –5.9 (–11.1 to –0.6)** –1.2 (–6.9 to 4.4) 1.9 (0.4–9.8)
PON1192
RR –4.4 (–12.4 to 3.6) 0.38 –2.1 (–8.3 to 4.0) 0.36 4.8 (0.8–31.1)* 0.20
QR –1.3 (–4.9 to 2.4) 0.7 (–2.6 to 4.0) 1.2 (0.5–3.3)
QQ –7.4 (–13.0 to –1.9)** –4.7 (–10.4 to 1.0) 6.1 (1.0–39.3)*
DE DAPs
PON1–108
CC –0.3 (–7.2 to 6.7) 0.84 0.9 (–4.9 to 6.8) 0.66 7.4 (0.6–93.9) 0.44
CT –1.7 (–6.3 to 3.0) –2.2 (–6.5 to 2.1) 0.8 (0.2–2.8)
TT –3.4 (–8.8 to 2.1) –1.5 (–7.3 to 4.2) 0.8 (0.1–4.3)
PON1192
RR 1.4 (–8.4 to 11.1) 0.47 4.5 (–2.9 to 11.9) 0.14 1.0 (0.1–8.2) 0.97
QR –1.1 (–5.2 to 3.0) –1.9 (–5.6 to 1.8) 0.8 (0.2–2.6)
QQ –2.5 (–8.7 to 3.6) –3.8 (–9.9 to 2.3) 1.2 (0.2–7.7)
aAdjusted for age at assessment, sex, parity, breast-feeding duration, HOME score, maternal PPVT, and household pov-
erty status. Bayley MDI and PDI models also included psychometrician and testing location; PDD models also included 
maternal depression. bInteraction p-value was calculated using a postestimation combined F-test (or chi-square test) for 
the two interaction variables between genotype and DAPs (e.g., 192QR × DAP and 192QQ × DAP). Conclusions regarding 
interaction were similar if a single interaction term with the number of C or Q alleles (0, 1, 2) was used instead. *p < 0.10. 
**p < 0.05. Eskenazi et al.
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diseases (Erlich et al. 2006; Leduc and Poirier 
2008; Paragh et al. 2002; Zintzaras and 
Hadjigeorgiou 2004). In addition, PON1 
polymorphisms and enzyme activities have 
been associated with autism spectrum disor-
der. In a family-based linkage study, D’Amelio 
et al. (2005) found that Caucasian-American, 
but not Italian, patients diagnosed with autism 
were more likely to carry the PON1192R allele 
and more likely, although not significantly, 
to carry the PON1–108T allele. In line with 
these results, Pasca et al. (2010) reported that 
ARYase levels and POase activity were sig-
nificantly lower in 50 Romanian autistic chil-
dren compared with 30 age- and sex-matched 
nonautistic controls, but they observed no 
differences in PON1192 or PON155 allelic fre-
quencies between groups (and they did not 
examine PON1–108). Another study (Serajee 
et al. 2004) also failed to find a relation of 
PON155 allelic frequency in a family-based 
association study of 196 trios but did not 
examine PON1–108 or PON1192.
In the above studies, autistic patients were 
diagnosed by clinicians. In the present study, 
we based PDD on maternal report of symp-
tomatology associated with autism-like behav-
ior, and these reports were not confirmed 
by a clinician’s assessment. Nevertheless, for 
the most part, our findings are in line with 
those reported by Pasca et al. and D’Amelio 
et al. (2005): We observed a nonsignificant 
increase in maternal report of PDD in pri-
marily Mexican-American children with the 
PON1–108T allele but not with the PON1192R 
allele, and we found that 2-year-olds with 
higher ARYase levels and children whose 
mothers had higher ARYase or POase mea-
sures during pregnancy were less likely to be 
reported by their mother as having PDD.
D’Amelio et al. (2005) hypothesized that 
genetic vulnerability in the presence of expo-
sure to OP pesticides may contribute to the 
development of childhood autism, especially 
in North America, where until recently OP 
pesticides have been more commonly used 
in homes than in Europe. OP pesticides can 
induce oxidative stress (Milatovic et al. 2006), 
and PON1 may protect the body from the 
effects of OP pesticides both through its anti-
oxidant properties and its ability to metabolize 
the activated form (e.g., chlorpyrifos-oxon) 
of the pesticides. We previously reported that 
with every 10-fold increase in DAP metab-
olites concentrations in the urine of the 
women in this study during pregnancy, we 
found more than a doubling in odds of their 
reporting signs of PDD in their 2-year-olds. 
Nevertheless, we observed no evidence that 
PON1 genotype or enzyme activity modifies 
this association as suggested by the hypothesis 
of D’Amelio et al. (2005). However, given the 
lack of clinical diagnosis and that our sam-
ple sizes when stratified by PON1 genotype 
were relatively small, this hypothesis cannot 
be rejected.
Few studies have tested the hypothesis 
that PON1 genotype modifies the effects of 
pesticide exposure on neuropsychologic func-
tioning. One study from Israel demonstrated 
increased frontal cortical brain activity and 
decreased temporal lobe activity in pesticide-
exposed workers with PON1192R compared 
with either those without the R allele or unex-
posed adults (Browne et al. 2006). Only one 
previous study has examined the ability of 
PON1 enzyme to modify the association of 
OP pesticide exposure and neurobehavioral 
end points in children. Engel et al. (2007) 
found that DAP metabolite levels during 
pregnancy were associated with an increase in 
abnormal reflexes in the neonates as assessed 
on the Brazelton Neonatal Assessment Scale, 
and the association between DAP concentra-
tions, specifically DM DAPs, and abnormal 
reflexes was strongest in the infants born to 
women with the lowest levels of ARYase.
In the present study, we extend the 
observations of Engel et al. (2007) to tod-
dlers. Although we find a clear relationship 
of PON1–108 genotype with MDI scores and, 
to a lesser extent, PDI scores and a trend of 
increasingly stronger associations of maternal 
DAPs and MDI scores, we cannot provide 
firm evidence that the PON1 genotype or 
phenotype modifies the relation of exposure 
and mental development. Recent studies 
demonstrate that PON1 is a multifunctional 
enzyme, and it plays a significant role in 
protection against oxidative stress and lipid 
peroxidation in addition to OP detoxifica-
tion. Thus, it is possible that the relationship 
between PON1 and mental development is 
more strongly influenced by the role of PON1 
in protection from oxidative stress than by 
its OP pesticide detoxification capabilities, 
which may explain the absence of strong 
effect modification. Further, other pesticides 
not hydrolyzed by PON1, including mala-
thion (devolves to DM DAPs), have been 
shown to induce oxidative stress (Durak et al. 
2009; Franco et al. 2009). This may explain 
why we observed stronger associations of neu-
robehavior with DM DAPs than with DE 
DAPs (after stratification by PON1 genotype) 
despite the fact that DEs are derived from 
known PON1 substrates (chlorpyrifos-oxon 
and diazoxon).
Our research is limited in a number of 
ways. DAP metabolites are an imperfect meas-
ure of OP pesticide exposure given the short 
half-life of OP pesticides, the variability in 
exposure over time, differences in metabolism 
that may affect excretion (Wessels et al. 2003), 
and the potential for exposure to preformed 
DAPs in the environment (Quirós-Alcalá 
2010). In fact, it is possible that because the 
PON1 gene is involved with the ability to 
metabolize OP pesticides, levels of excreted 
DAPs may be related both to exposure and 
to genetics. We are currently examining 
this issue by analyzing the interrelationship 
of blood OP pesticide measurements, gen-
otype, and urinary DAP concentrations in 
this cohort. Our study results may not be 
generalizable given this unique cohort of pri-
marily Mexican-American children from an 
agricultural area. Other populations may have 
a different spectrum of OP pesticide expo-
sures and PON1 allelic distributions, which 
are known to vary widely among different 
ethnic groups (Chen et al. 2003; Rojas-Garcia 
et al. 2005). The relationship between geno-
type and enzyme activities in adults, however, 
appears to be comparable in different ethnic 
groups (Costa et al. 2005).
Another limitation is that we have con-
structed a fairly simple model for neuro-
behavioral development. Although we have 
examined and/or controlled for a number of 
key potential confounders, neurobehavioral 
development is complex and multifacto-
rial, and numerous genes and environmental 
agents, social, biological, physical, and chemi-
cal, are likely involved. In addition, when 
data are stratified by genotype, the fairly large 
numbers of this study become relatively small 
in each stratum, making it difficult to find 
significant statistical interactions.
We have not examined other genes that 
have been implicated in the hypothesized 
gene–environment interaction such as RELN 
or AChE or other PON1 polymorphisms 
(Moy and Nadler 2008). We have recently 
shown that other PON1 polymorphisms 
are also associated with ARYase and POase 
measurements in mothers and children of 
the CHAMACOS cohort; however, most of 
them were in strong linkage disequilibrium 
with those examined in this report (Huen 
et al. 2010) and are unlikely to affect the 
associations noted here. Haplotype analysis 
is sometimes proposed as a more informative 
approach for analysis of genetic effects, but 
we did not see an improvement of association 
with neurodevelopment using haplotypes in 
this study (data not shown). Additionally, we 
did not find a significant difference in func-
tional effects of PON1 haplotypes compared 
with multiple polymorphisms in predicting 
PON1 enzyme measurements (Holland et al. 
2006; Huen et al. 2010).
The strengths of this study are that we 
have focused on an agricultural population 
with relatively high levels of OP pesticide 
exposures, that we have measured this expo-
sure during pregnancy in this longitudinal 
birth cohort study, and that we have geno-
typed and measured enzyme activity in moth-
ers and children at birth and during infancy.
In summary, we have found that PON1–108T 
allele is related to mental development and, to a PON1, organophosphates, and neurodevelopment
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lesser extent, psychomotor development in tod-
dlers. This study adds to the growing evidence 
that the PON1 gene is associated with an array 
of neurologic end points in adults and in chil-
dren. Although we did not observe a statistical 
interaction between prenatal OP pesticide expo-
sure as measured by pesticide metabolites and 
PON1, we did observe a consistent trend, and 
our results need replication in other populations 
and perhaps pooling with similar studies to pro-
vide adequate sample sizes.
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